JP2015502346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502346A5 JP2015502346A5 JP2014541386A JP2014541386A JP2015502346A5 JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5 JP 2014541386 A JP2014541386 A JP 2014541386A JP 2014541386 A JP2014541386 A JP 2014541386A JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- item
- disorder
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000002092 calcimimetic effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 2
- 230000002037 soft tissue calcification Effects 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558389P | 2011-11-10 | 2011-11-10 | |
| US61/558,389 | 2011-11-10 | ||
| PCT/US2012/064717 WO2013071262A1 (en) | 2011-11-10 | 2012-11-12 | Calcimimetics and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Division JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502346A JP2015502346A (ja) | 2015-01-22 |
| JP2015502346A5 true JP2015502346A5 (cg-RX-API-DMAC7.html) | 2016-01-07 |
| JP6204369B2 JP6204369B2 (ja) | 2017-09-27 |
Family
ID=47258113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541386A Active JP6204369B2 (ja) | 2011-11-10 | 2012-11-12 | カルシウム模倣薬およびその使用方法 |
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140315809A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2776129B2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6204369B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104168955A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012335009B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2854911C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202086A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX355063B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013071262A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| EP4154900B1 (en) | 2009-07-29 | 2024-08-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| HRP20171092T1 (hr) * | 2013-06-28 | 2017-10-06 | Amgen Inc. | Stabilna tekuća formulacija amg 416 (velkalcetid) |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| WO2016062289A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途 |
| EP3226891B1 (en) | 2014-12-05 | 2025-06-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| JP6868561B2 (ja) * | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| HK1257341A1 (zh) | 2015-08-17 | 2019-10-18 | Alexion Pharmaceuticals, Inc. | 硷性磷酸酯的制造 |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| CN106928320B (zh) * | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| CN109152820A (zh) | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| US11450405B2 (en) * | 2018-10-18 | 2022-09-20 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| TW202122410A (zh) * | 2019-12-09 | 2021-06-16 | 大陸商北京拓界生物醫藥科技有限公司 | 鈣敏感受體激動劑化合物及其應用 |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2022052471A1 (zh) * | 2020-09-10 | 2022-03-17 | 陕西麦科奥特科技有限公司 | 双特异性融合多肽化合物 |
| CN117042791A (zh) | 2021-02-12 | 2023-11-10 | 阿雷克森制药公司 | 碱性磷酸酶多肽及其使用方法 |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| US20240269227A1 (en) * | 2021-06-08 | 2024-08-15 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist composition and application thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6147186A (en) * | 1996-07-31 | 2000-11-14 | The General Hospital Corporation | Parathyroid hormone-related peptide analogs |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| AU2001278956B2 (en) | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
| WO2003013543A1 (en) * | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
| EP1858553A2 (en) * | 2005-03-17 | 2007-11-28 | Amgen Inc., | Methods of decreasing calcification |
| JP5645408B2 (ja) | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| WO2008122010A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals, Inc. | Pharmaceutical calcimimetics |
| EP4154900B1 (en) * | 2009-07-29 | 2024-08-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2012
- 2012-11-12 MX MX2014005662A patent/MX355063B/es active IP Right Grant
- 2012-11-12 CA CA2854911A patent/CA2854911C/en active Active
- 2012-11-12 EP EP12791926.4A patent/EP2776129B2/en active Active
- 2012-11-12 AU AU2012335009A patent/AU2012335009B2/en active Active
- 2012-11-12 CN CN201280066707.1A patent/CN104168955A/zh active Pending
- 2012-11-12 WO PCT/US2012/064717 patent/WO2013071262A1/en not_active Ceased
- 2012-11-12 HK HK15102648.5A patent/HK1202086A1/xx unknown
- 2012-11-12 US US14/357,702 patent/US20140315809A1/en not_active Abandoned
- 2012-11-12 CN CN201910103503.4A patent/CN109985228A/zh active Pending
- 2012-11-12 JP JP2014541386A patent/JP6204369B2/ja active Active
-
2016
- 2016-03-01 US US15/057,742 patent/US20160175383A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/603,279 patent/US20170252397A1/en not_active Abandoned
- 2017-06-23 JP JP2017123032A patent/JP2017160269A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502346A5 (cg-RX-API-DMAC7.html) | ||
| JP2015522576A5 (cg-RX-API-DMAC7.html) | ||
| MX2011012131A (es) | Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2013518815A5 (cg-RX-API-DMAC7.html) | ||
| JP2010202664A5 (cg-RX-API-DMAC7.html) | ||
| JP2012529293A5 (cg-RX-API-DMAC7.html) | ||
| JP2012115277A5 (cg-RX-API-DMAC7.html) | ||
| JP2013539454A5 (cg-RX-API-DMAC7.html) | ||
| JP2013520405A5 (cg-RX-API-DMAC7.html) | ||
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| JP2011105739A5 (cg-RX-API-DMAC7.html) | ||
| JP2014051497A5 (cg-RX-API-DMAC7.html) | ||
| JP2018538356A5 (cg-RX-API-DMAC7.html) | ||
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| JP2012136541A5 (cg-RX-API-DMAC7.html) | ||
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| JP2016504275A5 (cg-RX-API-DMAC7.html) | ||
| EA201691759A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| JP2013503110A5 (cg-RX-API-DMAC7.html) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| JP2017511377A5 (cg-RX-API-DMAC7.html) | ||
| JP2012513193A5 (cg-RX-API-DMAC7.html) | ||
| MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
| EP2598158A4 (en) | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |